EFPIA - NEWSLETTER

Trouble reading this email? View it in your browser


		EFPIA Newsletter 20 June 2024

EU HTA: If we want faster access to cancer treatment for all, we need to get it right

By Nathalie Moll, Director General, EFPIA

How will the new EU Health Technology Assessments (HTA) Regulation facilitate improving cancer outcomes?

Our aspiration is to get these treatments to patients as quickly as possible. However, the imminent implementation of the HTA Regulation and introduction of Joint Clinical Assessments (JCA) in 2025 create uncertainty about the speed at which breakthrough cancer treatments will reach patients in the future.

Is the EU HTA Regulation ready for vaccine innovation and fill-in the promise of improved availability?

In just 7 months from now, the EU HTA Regulation (HTAR) will become applicable. The objectives set aside by the EU legislator will stop being a theoretical concept, hopefully translating into key performance indicators: efficiency of resources’ use, strengthening the HTAs quality, improvement of business predictability, and most importantly, improvement of the availability of innovative health technologies.

How will the HTAR score when it comes to its preparedness and objectives’ fulfilment for vaccines?

Learn more here.

Events

Estimands framework in action, the Alzheimer’s disease case
02 July 2024 (Online Event)

Join us for a webinar to explore the application of the estimand framework in Phase 3 Alzheimer's disease trials Read more

DIA Medical Information & Communications Conference
24 September 2024 (London, UK)

The 2024 DIA Medical Information and Communications Conference is designed for medical information professionals and... Read more

DIA Health Technology Assessment Forum
14 October 2024 (Brussels, Belgium)

Creating a successful European HTA system to accelerate patient's access. Read more

Executive MSc Healthcare Decision-Making at LSE
31 October 2024 (London, UK)

Discover the transformative Executive MSc in Healthcare Decision-Making, a dynamic partnership between NICE and LSE.... Read more

What we are reading

The 2024 Barometer of France's attractiveness to pharmaceutical companies
On 07 June 2024 (Leem)

Leem pinpoints the conditions required for sovereignty in health and industry to the benefit of patients, for a strong... Read more

Mosquito Borne Disease at the Paris Olympics: reducing the risk
On 30 May 2024 (Vaccines Europe)

With millions of fans and visitors, plus hundreds of athletes from across the globe... Read more

Accelerating clinical trials in the EU (ACT EU): transforming the EU clinical trials landscape...
On 23 May 2024 (nature)

Accelerating Clinical Trials in the EU (ACT EU) is an initiative developed by the European Commission, Heads of Medicines... Read more

About the EFPIA newsletter

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

Tel: +32 (0)2 626 25 55
E-mail:Communications@efpia.eu